Therapy of Angiosarcoma with Thalidomide and Lenalidomide.

Autor: Mattes MJ; Center for Molecular Medicine and Immunology, Garden State Cancer Center, Belleville, New Jersey, USA., Mattes JA; Psychopharmacology Research Association, Princeton, New Jersey, USA., Groisberg R; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Mattes MD; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Jazyk: angličtina
Zdroj: Case reports in oncology [Case Rep Oncol] 2021 Nov 08; Vol. 14 (3), pp. 1580-1585. Date of Electronic Publication: 2021 Nov 08 (Print Publication: 2021).
DOI: 10.1159/000519970
Abstrakt: Angiosarcoma is an uncommon malignancy with a poor prognosis. Systemic therapy options for patients with metastatic disease generally have limited effectiveness. In this case study, a 73-year-old male with metastatic angiosarcoma who previously declined chemotherapy and developed progressive disease after checkpoint inhibitor immunotherapy elected to try thalidomide based on 6 case reports describing its effectiveness. Thalidomide resulted in stable disease for 9 months, but due to severe neuropathy as a side effect, lenalidomide was then substituted for thalidomide. The patient continued to have stable disease on lenalidomide for an additional 16 months and ongoing. This is the first case study to report on effective treatment of angiosarcoma with lenalidomide. Further investigation of lenalidomide in the management of angiosarcoma is warranted.
Competing Interests: The authors have no conflicts of interest to declare.
(Copyright © 2021 by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje